Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biotechnology

- PMLiVE

Pascale Richetta moves from AbbVie to UCB

She joins the biopharmaceutical company as executive vice president

Roche Basel Switzerland

AbbVie and Roche hoping for speedy venetoclax approval

Leukaemia treatment could reach US and EU markets within months

- PMLiVE

AbbVie takes ‘one-size-fits-all’ HCV regimen into phase III

Comes shortly after Gilead wins priority FDA review for its 'pan-genotypic' treatment

Gilead Sciences

Gilead steps into breach left by AbbVie as Galapagos’ partner

Deal worth $2bn to help rheumatoid arthritis drug filgotinib make it through to the market

- PMLiVE

Lucid behavioural change programmes recognised at PMEA

Agency wins awards for initiatives for AbbVieand Genzyme

- PMLiVE

AbbVie takes Company of the Year at PMEA 2015

Firm rewarded for patient-centricity, whileAstellas is highly commended

- PMLiVE

Amgen’s biosimilar shows clinical equivalence with Humira

ABP 501 as effective as AbbVie's blockbuster in phase III rheumatoid arthritis trial

- PMLiVE

AbbVie looks to put bronchiolitis awareness back on the agenda

Relaunches More Than a Cold campaign

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

- PMLiVE

AbbVie drops Galapagos JAK inhibitor to focus on ABT-494

Believes ABT-494 has potential to become best-in-class therapy

- PMLiVE

AbbVie’s Humira wins ninth US approval

FDA approves multi-blockbuster for inflammatory skin disease

Bristol-Myers Squibb (BMS) building

BMS’ myeloma treatment accepted for priority review

If approved elotuzumab will be marketed as Empliciti

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links